Orgaran (Danaparoid Sodium)

Orgaran is used in the anticoagulation pathway to treat and prevent clot‑related conditions.

• Venous thromboembolism: prevents new clot formation and treats existing deep‑vein thrombosis or pulmonary embolism.
• Heparin‑induced thrombocytopenia (HIT): provides effective anticoagulation when heparin therapy is contraindicated.
• Surgical prophylaxis: reduces risk of peri‑operative thrombotic events in high‑risk orthopedic or cardiac procedures.

• Danaparoid Sodium exerts its anticoagulant effect by potentiating antithrombin III and heparin cofactor II, leading to selective inhibition of factor Xa. This reduces thrombin generation without markedly affecting factor IIa, resulting in decreased fibrin clot formation while preserving some platelet function. The drug’s heparinoid structure confers a predictable pharmacodynamic profile suitable for intravenous administration.

Adverse reactions to Orgaran may vary in frequency and severity.

Common Side Effects

• Injection site pain or erythema
• Mild bleeding or bruising
• Nausea or vomiting
• Headache
• Transient elevation of liver enzymes
• Fever

Serious or Rare Side Effects

• Major hemorrhage
• Severe thrombocytopenia
• Anaphylactic or severe hypersensitivity reactions
• Disseminated intravascular coagulation
• Acute renal failure
• Adrenal hemorrhage

Before initiating Orgaran therapy, clinicians should observe several precautionary measures.

• Bleeding risk assessment: evaluate patient history for active bleeding or recent surgery.
• Coagulation monitoring: regularly check activated partial thromboplastin time or anti‑Xa levels.
• Renal function evaluation: adjust use in patients with impaired kidney function.
• History of HIT: confirm diagnosis before selecting Danaparoid.
• Concomitant anticoagulants: avoid or carefully dose other anticoagulant agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Orgaran can interact with other medicines that affect haemostasis or drug metabolism.

Major Interactions (Avoid)

• Concurrent use with other anticoagulants (e.g., unfractionated heparin, warfarin, direct oral anticoagulants) may cause uncontrolled bleeding.
• Thrombolytic agents (e.g., alteplase) increase risk of severe hemorrhage.
• Antiplatelet drugs (e.g., clopidogrel, aspirin) when combined can amplify bleeding tendency.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may modestly increase bleeding risk.
• Selective serotonin reuptake inhibitors (SSRIs) can affect platelet aggregation.
• Certain antibiotics (e.g., vancomycin) may alter anticoagulant activity.
• Herbal supplements such as ginkgo biloba may potentiate anticoagulation.